Envveno Medical CORP 8-K filings

enVVeno Medical Corporation has filed an investor presentation on July 14, 2026, providing updates that may be used in discussions with investors and analysts.

enVVeno Medical Corporation announced FDA approval for a pivotal U.S. study of its non-surgical replacement venous valve, the enVVe System, for severe Chronic Venous Insufficiency.

enVVeno Medical Corporation announced it has regained compliance with Nasdaq's minimum bid price requirement and reported approximately $28 million in cash and investments as of December 31, 2025.

enVVeno Medical Corporation has completed a 1-for-35 reverse stock split, significantly reducing outstanding shares and proportionally adjusting equity awards.

enVVeno Medical Corporation's stockholders re-elected directors, approved executive compensation and auditor, but rejected a new equity incentive plan while granting authority for a reverse stock split.

enVVeno Medical Corporation's Board of Directors approved an amendment to its bylaws, reducing the quorum requirement for stockholder meetings to thirty-three and one-third percent of voting power.

enVVeno Medical Corporation received an unfavorable FDA appeal decision for its VenoValve Premarket Approval application, leading the company to shift focus to its next-generation enVVe device.

enVVeno Medical Corporation has initiated an At-the-Market equity program to sell up to $50 million of common stock through Ladenburg Thalmann & Co. Inc.

enVVeno Medical Corporation received a Nasdaq notification for failing to meet the minimum bid price requirement, initiating a 180-day compliance period.

enVVeno Medical Corporation received a not-approvable letter from the FDA for its VenoValve Premarket Approval application.

enVVeno Medical Corporation announced the appointment of Jennifer Bright as its new Chief Financial Officer, effective May 19, 2025, replacing Craig Glynn, who resigned on the same day.

enVVeno Medical Corporation reports Marcum LLP's resignation as auditors and the engagement of CBIZ CPAs P.C. as the new independent registered public accounting firm, effective April 17, 2025.

enVVeno Medical Corporation successfully held its 2024 annual meeting, electing two Class I directors, approving executive compensation, and ratifying its independent auditor.

enVVeno Medical Corporation closed a public offering of common stock and pre-funded warrants, raising approximately $15 million in gross proceeds.

enVVeno Medical reports significant clinical improvement in patients from its VenoValve pivotal trial, with 72% showing clinically meaningful benefit.

enVVeno Medical reports that 97% of patients in the VenoValve study showed clinical improvement at six months, with 74% demonstrating clinically meaningful benefit.